Video Insights
Advertisement
The Two Onc Docs review QOL related to doublet ADT with darolutamide, niraparib with abiraterone for mCSPC, and more.
The Two Onc Docs review the 5-year follow-up data on adjuvant pembro and a final analysis on ipi/nivo for metastatic disease.
The Two Onc Docs weigh IO for BCG-refractory NMIBC, ctDNA monitoring for patients receiving gem/cis for MIBC, and more.
Dr. Machaalani highlights his study that evaluated the association between circulating KIM-1 and mRCC tumor biology.
Dr. James showcases an MMAI model to identify benefit from 2nd-generation ARPIs in hr/nm PCa patients from STAMPEDE.
Drs. Necchi and Tawagi break down in detail the first results of SURE-02 in patients with muscle-invasive bladder cancer.
Dr. Faltas highlights CLONEVO, a trial using preoperative abemaciclib in cisplatin-ineligible MIBC with ctDNA monitoring.
Dr. Hayne speaks about the ANZUP 101 trial results that evaluated the combination of mitomycin and BCG for NMIBC.
Drs. Ong and Roy detail a multinational real-world analysis of the IRONMAN registry on the significance of PSA>0.2.
Dr. Tagawa explains the rationale for EVOLUTION, a phase II analysis of Lu-PSMA-617 with ipilimumab and nivolumab in mCRPC.
Dr. Tagawa contextualizes a post hoc analysis on clonal hematopoiesis in those who received 177Lu-PSMA-617 or cabazitaxel.
Dr. Tagawa showcases the ProstACT Global trial, a phase III study of 177Lu-rosptamab in patients with mCRPC.
Dr. Tagawa breaks down the VIOLET study, a single-arm phase I/II first-in-human results of terbium-161Tb-PSMA-I&T.
Dr. McGregor shares the opening of the STRIKE trial, which investigates adding tivo to pembro in the mRCC adjuvant setting.
Dr. McGregor opens up about the expansion cohort of the phase 1 ARC-20 study, which looked at casdatifan plus cabozantinib.
Drs. Swami and Ciuro discuss adoption of treatment intensification, barriers to guideline-concordant care, and more in mHSPC.
Dr. Haas provides an update on a 5-year follow-up of KEYNOTE-564 and the survival benefits of adjuvant pembrolizumab for RCC.
Vitaly Margulis, MD, UT Southwestern Medical Center, walks through the ENLIGHTED trial interim analysis.
Drs. Galsky and Tawagi detail the event-free survival subgroup analyses based on disease stage from the CREST study.
Drs. Privé and Tagawa discuss the BULLSEYE trial, an analysis of Lutetium-177-PSMA-617 in oligometastatic HSPC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.